Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.

• Status: Completed
• Trial end date: 2017-05-15
• Target enrollment: 0
• Participant gender: All

Summary

This prospective study is intended to evaluate if carvedilol has any potential protective effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following cardiac catheterization in patients with moderate to high risk for CIN.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: rabab ahmed mohamed
• Collaborator: Cairo University
• Treatments: Atorvastatin; Carvedilol

Criteria

Inclusion Criteria:

• Patients aged between 18 and 70 years.

• Serum creatinine ≤ 1.5 mg/dL.

• Using a moderate dose of atorvastatin (40 mg or equivalent dose of other statins).

• Moderate to high-risk for CIN.

Exclusion Criteria:

• Patients suffering from ST-segment elevation myocardial infarction (STEMI)

• Patients need for immediate cardiac catheterization

• Elevated liver enzymes (Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) three times the upper limit of normal).

• Active infection.

• Any contraindication to carvedilol, or atorvastatin.

• Patients on regular use of vitamins, minerals.

• Using medication with antioxidant properties e.g., beta-carotene, vitamin E, vitamin C, selenium, theophylline or N-acetyl cysteine 7 days prior to CC.

• Hemodynamically unstable patients (defined as abnormal or unstable blood pressure, especially hypotension (blood pressure less than 90/60 mm Hg).

• Patients who required dialysis.

• Pregnancy.

• Using of carvedilol in the past three months.

• Using a nephrotoxic agent in the past 48 hours or exposure to a contrast agent in the past 7 days prior to cardiac catheterization.